Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof

Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof

US Patent 12427131 · Granted Sep 30, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Atrial natriuretic peptide engrafted antibodies2025
Substituted 5-fluoro-1H-pyrazolopyridines and their use2024
Substituted 5-fluoro-1H-pyrazolopyridines and their use2024
Substituted S-alaninate derivatives2024
7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof2022
Substituted 5-fluoro-1H-pyrazolopyridines and their use2022
Substituted 5-fluoro-1H-pyrazolopyridines and their use2022
Branched 3-phenylpropionic acid derivatives and their use2022
Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination 2021
Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination 2021
Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination 2021
7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof2021